REGN
NASDAQ · Biotechnology
Regeneron Pharmaceuticals
$756.73
+7.26 (+0.97%)
Performance
1D
—
1W
—
1M
—
3M
-3.05%
6M
+34.95%
1Y
+19.01%
YTD
-2.52%
Open$749.40
Previous Close$749.47
Day High$761.73
Day Low$747.77
52W High$821.11
52W Low$476.49
Volume—
Avg Volume673.5K
Market Cap80.50B
P/E Ratio17.87
EPS$41.55
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$763.91
Below
SMA 200
$631.14
Above
RSI (14)
59.8
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
36 analysts
Price Target
-89.9% upside
Current
$756.73
$756.73
Target
$76.80
$76.80
$61.79
$76.80 avg
$111.17
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 13.99B | 13.25B | 59.21B |
| Net Income | 4.39B | 3.74B | 1.62B |
| Profit Margin | 31.4% | 29.8% | 2.7% |
| EBITDA | 4.05B | 3.65B | 2.06B |
| Free Cash Flow | — | — | 732.77M |
| Rev Growth | +5.6% | +5.6% | +14.6% |
| Debt/Equity | 0.09 | 0.09 | 0.21 |
Dividend
Dividend Yield0.49%
Annual Dividend$3.44
Payout Ratio8.2%
Frequencyquarterly
Ex-Dividend—
Pay Date—
Recent Insider Activity
All Insiders →| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 3 | RYAN ARTHUR F | Sale | 17,796 | $777.46 | $13.84M |
| Mar 3 | RYAN ARTHUR F | Sale | 17,794 | $778.30 | $13.85M |
| Mar 3 | RYAN ARTHUR F | Sale | 17,789 | $779.69 | $13.87M |
| Mar 3 | RYAN ARTHUR F | Sale | 17,786 | $780.69 | $13.89M |
| Mar 3 | RYAN ARTHUR F | Sale | 17,784 | $781.21 | $13.89M |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company headquartered in Tarrytown, New York. The company discovers, develops, manufactures, and commercializes medicines for serious medical conditions including eye diseases, cardiovascular disease, cancer, inflammatory conditions, and rare genetic diseases. Regeneron's portfolio includes FDA-approved therapies developed using proprietary technologies such as VelociSuite for antibody generation and CRISPR-based gene editing platforms. The company employs a science-driven approach and maintains significant research collaborations with partners including Sanofi and Bayer.
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $211.12 | +1.90% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.16 | -0.22% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $136.88 | -1.00% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $453.74 | -0.27% | 29.2 | 115.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.16% | 139.7 | 43.84B |
| INSM | Insmed Inc | $147.60 | -0.48% | — | 30.09B |
REGN Frequently Asked Questions
What does Regeneron Pharmaceuticals do?
Regeneron earns the bulk of its revenue from two blockbuster drugs: Dupixent, a treatment for eczema, asthma, and other inflammatory conditions that has become one of the fastest-growing drugs in pharmaceutical history, and EYLEA, used to treat wet age-related macular degeneration and other retinal diseases. Beyond those anchors, it has a deep pipeline of antibody-based therapies covering oncology, cardiovascular disease, and rare genetic conditions. Its proprietary VelociSuite platform allows the company to generate drug candidates faster than most peers.
Is REGN stock a good investment?
Regeneron's investment case centers on Dupixent's continued growth across new indications and geographies — the drug is still penetrating many of its approved uses. The company has significant cash and generates strong free cash flow, allowing it to self-fund R&D without excessive dilution. The main risk is EYLEA patent pressure from biosimilar competition, which has already begun eroding that revenue stream. Valuation reflects quality biotech premiums, and the pipeline breadth provides some protection against single-drug concentration risk.
Who are Regeneron Pharmaceuticals's main competitors?
In atopic dermatitis and type 2 inflammation, AbbVie's Skyrizi and Rinvoq are major Dupixent challengers, along with Eli Lilly's Lebrikizumab. For EYLEA in the retinal disease space, Novartis's Beovu and Roche's Vabysmo compete directly. In oncology, Regeneron's Libtayo competes with established checkpoint inhibitors from Bristol-Myers Squibb (Opdivo) and Merck (Keytruda).
What makes REGN stock unique?
Unlike many biotechs that rely on a single platform, Regeneron built its moat around the VelociSuite antibody technology, which has generated multiple successful drugs and enabled collaborative deals with Sanofi and Bayer that de-risk development costs. The company is unusually founder-led, with its scientific co-founders still deeply involved in research direction, which has created a distinctive culture of scientific rigor that critics argue is harder to replicate than typical pharma R&D organizations.
Where is REGN trading today?
REGN last closed at $756.73, up 0.97% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $476.49 and a high of $821.11. The current price represents 81% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.
What are analyst ratings for REGN stock?
Among 36 analysts covering REGN, the consensus rating is Strong Buy — 27 rate it a buy, 9 hold, and 0 sell. The average price target sits at $76.80, implying 90% downside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.
How much revenue does Regeneron Pharmaceuticals generate?
Regeneron Pharmaceuticals generated $13.99B in revenue during fiscal year 2026, with $4.39B reaching the bottom line as net income. The net profit margin of 31.4% is strong by most industry standards.
What is the price-to-earnings ratio for REGN?
REGN trades at a P/E ratio of 17.87 on trailing earnings of $41.55 per share. That's roughly in line with the broader market average of ~20-25x. Comparing this multiple against Biotechnology sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.
How has REGN performed compared to last year?
Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: -3.05% (3M), +34.95% (6M), +19.01% (1Y), -2.52% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether REGN is outperforming or lagging the broader market.